⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ZBIO News
Zenas BioPharma, Inc. Common Stock
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
globenewswire.com
ZBIO
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ZBIO
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
globenewswire.com
ZBIO
Form 8-K
sec.gov
ZBIO
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
ZBIO
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ZBIO
Zenas BioPharma, Inc. Investigated by the Portnoy Law Firm
globenewswire.com
ZBIO
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation
accessnewswire.com
ZBIO
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
accessnewswire.com
ZBIO
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation
accessnewswire.com
ZBIO